VEGFA and hepatocellular carcinoma: Only one study aimed to assess the role of VEGF and VEGFR polymorphisms in clinical outcomes of HCC patients receiving sorafenib therapy, and it found that rs4604006 (VEGF‐C) T allele was significantly associated with patients’ progression‐free survival and overall survival (Scartozzi et al., 2014).